Literature DB >> 16108824

Skin-derived dendritic cells acquire and degrade the scrapie agent following in vitro exposure.

Joanne Mohan1, John Hopkins, Neil A Mabbott.   

Abstract

The accumulation of the scrapie agent in lymphoid tissues following inoculation via the skin is critical for efficient neuroinvasion, but how the agent is initially transported from the skin to the draining lymph node is not known. Langerhans cells (LCs) are specialized antigen-presenting cells that continually sample their microenvironment within the epidermis and transport captured antigens to draining lymph nodes. We considered LCs probable candidates to acquire and transport the scrapie agent after inoculation via the skin. XS106 cells are dendritic cells (DCs) isolated from mouse epidermis with characteristics of mature LC cells. To investigate the potential interaction of LCs with the scrapie agent XS106 cells were exposed to the scrapie agent in vitro. We show that XS106 cells rapidly acquire the scrapie agent following in vitro exposure. In addition, XS106 cells partially degrade the scrapie agent following extended cultivation. These data suggest that LCs might acquire and degrade the scrapie agent after inoculation via the skin, but data from additional experiments demonstrate that this ability could be lost in the presence of lipopolysaccharide or other immunostimulatory molecules. Our studies also imply that LCs would not undergo maturation following uptake of the scrapie agent in the skin, as the expression of surface antigens associated with LC maturation were unaltered following exposure. In conclusion, although LCs or DCs have the potential to acquire the scrapie agent within the epidermis our data suggest it is unlikely that they become activated and stimulated to transport the agent to the draining lymph node.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16108824      PMCID: PMC1802412          DOI: 10.1111/j.1365-2567.2005.02207.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  49 in total

Review 1.  C-type lectin receptors on dendritic cells and Langerhans cells.

Authors:  Carl G Figdor; Yvette van Kooyk; Gosse J Adema
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

2.  Down-regulation of Toll-like receptor expression in monocyte-derived Langerhans cell-like cells: implications of low-responsiveness to bacterial components in the epidermal Langerhans cells.

Authors:  Junko Takeuchi; Eiji Watari; Eiji Shinya; Yoshihiko Norose; Misako Matsumoto; Tsukasa Seya; Masahiko Sugita; Seiji Kawana; Hidemi Takahashi
Journal:  Biochem Biophys Res Commun       Date:  2003-07-04       Impact factor: 3.575

3.  Activation by prion peptide PrP106-126 induces a NF-kappaB-driven proinflammatory response in human monocyte-derived dendritic cells.

Authors:  Silvia M Bacot; Petra Lenz; Michelle R Frazier-Jessen; Gerald M Feldman
Journal:  J Leukoc Biol       Date:  2003-07       Impact factor: 4.962

4.  Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response.

Authors:  M Wykes; A Pombo; C Jenkins; G G MacPherson
Journal:  J Immunol       Date:  1998-08-01       Impact factor: 5.422

5.  Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration.

Authors:  M Cumberbatch; R J Dearman; I Kimber
Journal:  Immunology       Date:  1997-11       Impact factor: 7.397

6.  Scrapie infection can be established readily through skin scarification in immunocompetent but not immunodeficient mice.

Authors:  D M Taylor; I McConnell; H Fraser
Journal:  J Gen Virol       Date:  1996-07       Impact factor: 3.891

7.  Successive generation of antigen-presenting, dendritic cell lines from murine epidermis.

Authors:  S Xu; K Ariizumi; G Caceres-Dittmar; D Edelbaum; K Hashimoto; P R Bergstresser; A Takashima
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

8.  Prion protein expression in different species: analysis with a panel of new mAbs.

Authors:  G Zanusso; D Liu; S Ferrari; I Hegyi; X Yin; A Aguzzi; S Hornemann; S Liemann; R Glockshuber; J C Manson; P Brown; R B Petersen; P Gambetti; M S Sy
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

9.  HIV-1 selection by epidermal dendritic cells during transmission across human skin.

Authors:  J C Reece; A J Handley; E J Anstee; W A Morrison; S M Crowe; P U Cameron
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

10.  Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo.

Authors:  T De Smedt; B Pajak; E Muraille; L Lespagnard; E Heinen; P De Baetselier; J Urbain; O Leo; M Moser
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

View more
  13 in total

1.  Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent.

Authors:  Christopher S Greil; Ina M Vorberg; Anne E Ward; Kimberly D Meade-White; David A Harris; Suzette A Priola
Journal:  Virology       Date:  2008-08-08       Impact factor: 3.616

2.  A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner.

Authors:  Young Pyo Choi; Suzette A Priola
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

Review 3.  Brain dendritic cells: biology and pathology.

Authors:  Paul M D'Agostino; Andres Gottfried-Blackmore; Niroshana Anandasabapathy; Karen Bulloch
Journal:  Acta Neuropathol       Date:  2012-07-24       Impact factor: 17.088

4.  Processing of the bovine spongiform encephalopathy-specific prion protein by dendritic cells.

Authors:  Catherine Rybner-Barnier; Catherine Jacquemot; Céline Cuche; Grégory Doré; Laleh Majlessi; Marie-Madeleine Gabellec; Arnaud Moris; Olivier Schwartz; James Di Santo; Ana Cumano; Claude Leclerc; Françoise Lazarini
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Monitoring immune cells trafficking fluorescent prion rods hours after intraperitoneal infection.

Authors:  Theodore E Johnson; Brady A Michel; Crystal Meyerett; Angela Duffy; Anne Avery; Steven Dow; Mark D Zabel
Journal:  J Vis Exp       Date:  2010-11-19       Impact factor: 1.355

6.  Accelerated prion replication in, but prolonged survival times of, prion-infected CXCR3-/- mice.

Authors:  Constanze Riemer; Julia Schultz; Michael Burwinkel; Anja Schwarz; Simon W F Mok; Sandra Gültner; Theresa Bamme; Stephen Norley; Frank van Landeghem; Bao Lu; Craig Gerard; Michael Baier
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

7.  Accelerated prion disease pathogenesis in Toll-like receptor 4 signaling-mutant mice.

Authors:  Daryl S Spinner; In Soo Cho; Seung Yong Park; Jae Il Kim; Harry C Meeker; Xuemin Ye; Giuseppe Lafauci; Daniel J Kerr; Michael J Flory; Bo Sook Kim; Regina B Kascsak; Thomas Wisniewski; William R Levis; Georgia B Schuller-Levis; Richard I Carp; Eunkyue Park; Richard J Kascsak
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

8.  Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease.

Authors:  Christina D Orrú; Jue Yuan; Brian S Appleby; Baiya Li; Yu Li; Dane Winner; Zerui Wang; Yi-An Zhan; Mark Rodgers; Jason Rarick; Robert E Wyza; Tripti Joshi; Gong-Xian Wang; Mark L Cohen; Shulin Zhang; Bradley R Groveman; Robert B Petersen; James W Ironside; Miguel E Quiñones-Mateu; Jiri G Safar; Qingzhong Kong; Byron Caughey; Wen-Quan Zou
Journal:  Sci Transl Med       Date:  2017-11-22       Impact factor: 17.956

Review 9.  Cellular aspects of prion replication in vitro.

Authors:  Andrea Grassmann; Hanna Wolf; Julia Hofmann; James Graham; Ina Vorberg
Journal:  Viruses       Date:  2013-01-22       Impact factor: 5.048

10.  Dissociation of infectivity from seeding ability in prions with alternate docking mechanism.

Authors:  Michael B Miller; James C Geoghegan; Surachai Supattapone
Journal:  PLoS Pathog       Date:  2011-07-14       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.